<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558153</url>
  </required_header>
  <id_info>
    <org_study_id>NL44059.058.13</org_study_id>
    <nct_id>NCT02558153</nct_id>
  </id_info>
  <brief_title>RCT of Paclitaxel DEB Compared to Standard PTA in Dialysis Fistula</brief_title>
  <acronym>APERTO</acronym>
  <official_title>A Randomized Trial of Aperto Paclitaxel Eluting Dilatation Catheter Compared to POBA in Dialysis Fistula</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groene Hart Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Archer Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groene Hart Ziekenhuis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter randomized clinical trial of paclitaxel drug-eluting balloon (DEB) versus&#xD;
      standard percutaneous transluminal angioplasty (PTA) to reduce restenosis in 150 patients&#xD;
      with haemodialysis access stenoses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective multicenter randomized (1:1) Investigator Sponsored Trial, in which 150&#xD;
      consecutive patients candidates for percutaneous intervention of haemodialysis access will be&#xD;
      randomly assigned to one of two study arms:&#xD;
&#xD;
        1. Treatment Arm: paclitaxel drug-eluting balloon (DEB) dilatation using the APERTO-balloon&#xD;
&#xD;
        2. Control Arm: standard percutaneous transluminal angioplasty (PTA).&#xD;
&#xD;
      The aim is to evaluate the safety and efficacy of paclitaxel drug-eluting balloon (DEB) for&#xD;
      the reduction of restenosis in haemodialysis shunts compared to standard percutaneous&#xD;
      transluminal angioplasty (PTA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">July 3, 2019</completion_date>
  <primary_completion_date type="Actual">July 3, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adequate functioning of the hemodialysis access</measure>
    <time_frame>12 months</time_frame>
    <description>Period of adequate functioning of the hemodialysis access after treatment, defined according to the NKF-DOQI protocol criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>device success</measure>
    <time_frame>index procedure (day 0)</time_frame>
    <description>ability of the DEB to be delivered, inflated at pressure ≤ RBP, and retrieved from the Target Lesion without burst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>index procedure (day 0)</time_frame>
    <description>achievement of a lumen diameter of at least 70% of the nominal diameter of either the DEB or the post dilatation PTA balloon (whichever is bigger) by visual estimate and without bail-out stenting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>12 months</time_frame>
    <description>improvement in haemodialysis access failure and resumption of normal dialysis for at least one dialysis session after the index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>Index procedure (day 0)</time_frame>
    <description>Technical Success without the occurrence of MAE (MAE defined here as: death, stroke, thrombotic occlusion, allergic reaction, pulmonary events (including pulmonary edema)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAE - major adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>MAE defined as: death or stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thrombotic occlusion of target lesion</measure>
    <time_frame>12 months</time_frame>
    <description>thrombotic occlusion of target lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thrombotic occlusion of target hemodialysis access</measure>
    <time_frame>12 months</time_frame>
    <description>thrombotic occlusion of target hemodialysis access</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven Target Lesion Revascularization (TLR)</measure>
    <time_frame>12 months</time_frame>
    <description>Clinically driven Target Lesion Revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven Target Shunt Revascularization (TSR)</measure>
    <time_frame>12 months</time_frame>
    <description>Clinically driven Target Shunt Revascularization (TSR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Complication of Hemodialysis</condition>
  <condition>Vascular Access Complication</condition>
  <arm_group>
    <arm_group_label>DEB - drug eluting balloon (APERTO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting APERTO balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard PTA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug-eluting balloon (POBA, plain old balloon angioplasty).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DEB, drug eluting balloon</intervention_name>
    <description>Percutaneous angioplasty performed with a DEB - drug eluting balloon</description>
    <arm_group_label>DEB - drug eluting balloon (APERTO)</arm_group_label>
    <other_name>Paclitaxel eluting balloon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>standard PTA</intervention_name>
    <description>Percutaneous angioplasty performed with a standard balloon</description>
    <arm_group_label>standard PTA</arm_group_label>
    <other_name>POBA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All criteria 1-10 must apply for inclusion.&#xD;
&#xD;
          1. Age &gt; 18 years and &lt; 90 years&#xD;
&#xD;
          2. Patient or legally authorized representative providing written informed consent&#xD;
&#xD;
          3. Patient willing and likely to comply with the follow up schedule&#xD;
&#xD;
          4. Patients with previously well functioning hemodialysis access on the arm presenting&#xD;
             with any of the following clinical abnormalities as defined in the NKF-DOQI-protocol&#xD;
             criteria (National Kidney Foundation 2000):&#xD;
&#xD;
               -  Abnormal physical examination findings (change in bruits, thrill, pulse, etc&#xD;
&#xD;
               -  Abnormal urea recirculation measurements&#xD;
&#xD;
               -  Elevated venous pressure during dialysis&#xD;
&#xD;
               -  Decreased access flow&#xD;
&#xD;
               -  Previous thrombosis in the access line&#xD;
&#xD;
               -  Development of collateral veins&#xD;
&#xD;
               -  Limb swelling&#xD;
&#xD;
               -  Low arterial pressure during dialysis&#xD;
&#xD;
               -  Unexplained decreases in dialysis dose&#xD;
&#xD;
          5. Target Lesion is hemodynamically relevant and consists of MLD ≤ 3 mm. For enrolment&#xD;
             this criterium is judged by the local investigator. For final analysis this criterium&#xD;
             is based on the result of central reading of the angiogram.&#xD;
&#xD;
          6. Target Lesion(s) is a de-novo or (non-stent) restenosis&#xD;
&#xD;
          7. Target lesion(s) in dialysis fistulas is located at the anastomosis or in the outflow&#xD;
             venous trajectory up to the level (but excluding) the subclavian vein&#xD;
&#xD;
          8. Target lesion(s) in dialysis grafts is located at the arterial or venous anastomosis,&#xD;
             inside the graft, or in the outflow venous trajectory up to the level (but excluding)&#xD;
             the subclavian vein&#xD;
&#xD;
          9. Multiple Target Lesions are allowed per patient which can be treated by a number of&#xD;
             APERTO DEB with aggregate max length of 160 mm&#xD;
&#xD;
         10. NON Target Lesions (i.e. in the subclavian vein) must be successfully treated with&#xD;
             standard PTA prior to the Target Lesion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None of criteria 1-12 must apply for inclusion.&#xD;
&#xD;
          1. Patients unable to give informed consent&#xD;
&#xD;
          2. Patients enrolled in another study with any investigational drug or device&#xD;
&#xD;
          3. Patients previously enrolled in the APERTO trial.&#xD;
&#xD;
          4. Female patients of child bearing potential without a negative pregnancy test at the&#xD;
             time of intervention&#xD;
&#xD;
          5. Major surgical procedures within 30 days prior to this study or planned within 30 days&#xD;
             of entry into this study&#xD;
&#xD;
          6. Patients previously treated with a DEB in the hemodialysis access.&#xD;
&#xD;
          7. Patients with a trombosed hemodialysis access.&#xD;
&#xD;
          8. Immature hemodialysis access (unusable due to insufficient shunt flow volume)&#xD;
&#xD;
          9. Lesion treated within 30 days prior to screening&#xD;
&#xD;
         10. Failure to successfully treat non-target lesions prior the Target Lesion&#xD;
&#xD;
         11. In stent restenosis&#xD;
&#xD;
         12. Patients with any known allergy, hypersensitivity or intolerance to ASA, clopidogrel&#xD;
             or ticlopidine, paclitaxel, or contrast medium.&#xD;
&#xD;
         13. Graft infection&#xD;
&#xD;
         14. Life expectancy &lt; 1 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter MT Pattynama, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groene Hart Ziekenhuis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <state>Friesland</state>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Medisch Centrum. Department of radiology</name>
      <address>
        <city>Heerlen</city>
        <state>Limburg</state>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Lucas Andreas Hospital</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1061 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <state>ZH</state>
        <zip>2803 HH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <state>Zuid Holland</state>
        <zip>2512 VA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 7, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groene Hart Ziekenhuis</investigator_affiliation>
    <investigator_full_name>Dr Peter M.T. Pattynama</investigator_full_name>
    <investigator_title>MD, PhD. Interventional radiologist</investigator_title>
  </responsible_party>
  <keyword>drug eluting balloon</keyword>
  <keyword>percutaneous balloon angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

